Limited farm application is advised for this product, recommended solely as a final option. Prior to use, please consult your veterinarian for additional guidance.
This product is indicated for the treatment of infections attributed to the following bacteria susceptible to enrofloxacin:
 
Chickens:
 
Mycoplasma gallisepticum
Mycoplasma synoviae
Avibacterium paragallinarum
Pasteurella multocida
Escherichia coli
 
Turkeys:
 
Mycoplasma gallisepticum
Mycoplasma synoviae
Pasteurella multocida
Escherichia coli
 
For optimal outcomes, professional advice and adherence to veterinary direction are essential.
 
Target species
 
Broilers, broiler breeders, replacement chickens, turkeys. Indications for use
 
Treatment of infections caused by the following bacteria susceptible to enrofloxacin:
 
Chickens
 
Mycoplasma gallisepticum Mycoplasma synoviae Avibacterium paragallinarum Pasteurella multocida Turkeys Mycoplasma gallisepticum Mycoplasma synoviae Pasteurella multocida
 
Contraindications
 
Do not use for prophylaxis.
 
Do not use when resistance/cross-resistance to (fluoro)quinolones is known to occur in the flock intended for treatment. Infections caused by Streptococcus spp., because of only marginal susceptibility to enrofloxacin. Do not use in other animals. Do not use in case of hypersensitivity to the active substance, or to any of the excipients.
 
Special warnings for each target species
 
Treatment of Mycoplasma spp. infections may not eradicate the organism.
 
Special precautions for use in animals
 
Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross-resistance. Since enrofloxacin was first authorised for use in poultry, there has been widespread reduction in susceptibility of E. coli to fluoroquinolones and emergence of resistant organisms. Resistance has also been reported in Mycoplasma synoviae in the EU. As enrofloxacin will be partly excreted via kidneys, elimination will be delayed in cases with kidney disorders.
 
Special precautions to be taken by the person administering the veterinary medicinal product to animals
 
Personal protective equipment consisting of impervious gloves should be worn when handling the veterinary medicinal product. Wash any splashes from skin or eyes immediately with water. Wash hands and exposed skin after use. Do not eat, drink or smoke while using the product.
 
Other precautions
 
After the end of treatment, the watering system should be cleaned appropriately to prevent the intake of remaining subtherapeutic doses of the drug, which may lead to resistance.
 
Adverse reactions
 
Locomotion disturbances, as a result of damage to joint cartilage, cannot be excluded in cases where fluoroquinolones are used during the growing period, particularly at higher temperatures, when consumption of medicated water is drastically increased for longer periods.
 
Use during pregnancy and lactation
 
Laying birds:
 
Do not use in replacement birds within 14 days of coming into lay.
 
Interactions
 
When combined with tetracyclines and macrolide antibiotics, enrofloxacin may produce an antagonistic effect. Resorption of enrofloxacin may be reduced, when it is combined with substances containing magnesium or aluminium. The serum level of theophylline may increase when it is combined with enrofloxacin. Do not combine enrofloxacin with non steroidal antiphlogistics. Increased influx of the air (admixing CO2 from the air) into medicated drinking water may result in precipitation of enrofloxacin. Precipitation of the salt of enrofloxacin and alkalis may occur at higher concentration of calcium and magnesium in the water system during intermediate dilution in the dosage devices.